MicroRNA‑3907 promotes the proliferation and migration of sebaceous gland carcinoma of the eyelid by targeting thrombospondin 1

Zhang,Chuanli; Zhu,Limin; Liu,Xun; Jiang,Meixia; Tang,Qin; Xu,Fei; Lin,Tingting; Dong,Lijie; He,Yanjin

doi:10.3892/ol.2021.13094

MicroRNA‑3907 promotes the proliferation and migration of sebaceous gland carcinoma of the eyelid by targeting thrombospondin 1

Authors:
- Chuanli Zhang
- Limin Zhu
- Xun Liu
- Meixia Jiang
- Qin Tang
- Fei Xu
- Tingting Lin
- Lijie Dong
- Yanjin He
View Affiliations

Affiliations: Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, P.R. China
Published online on: October 14, 2021 https://doi.org/10.3892/ol.2021.13094
Article Number: 833
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) play an important role in various types of carcinoma, including sebaceous gland carcinoma (SGC) of the eyelid. miR‑3907 was found to be highly expressed in lung cancer; however, to the best of our knowledge, the biological role of miR‑3907 in SGC has not previously been evaluated. The aim of the present study was to determine the role and mechanism of miR‑3907 in the occurrence and development of SGC. miR‑3907 was screened and identified as a novel upregulated miRNA in SGC tissues and cells, as determined using miRNA microarrays and reverse transcription‑quantitative (RT‑q) PCR analyses. Compared with the control group, cellular proliferation and migration were enhanced in the miR‑3907 mimics group, and decreased in the miR‑3907 inhibitor group. Moreover, miR‑3907 negatively regulated thrombospondin 1 (THBS1) expression, as shown by bioinformatics prediction, RT‑qPCR, western blotting and dual‑luciferase reporter assays. In addition, compared with the control group, the small interfering (si) siRNA‑THBS1 group exhibited enhanced proliferation and migration abilities, which were decreased in the THBS1 overexpression group. Furthermore, THBS1 overexpression was found to attenuate the stimulative effect of miR‑3907 mimics, and THBS1‑knockdown reversed the inhibitory effect of the miR‑3907 inhibitor in SGC cells. Collectively, the results of the present study indicated that miR‑3907 promoted the proliferation and migration of SGC by downregulating THBS1, and that this axis may be a potential target for the prognostic assessment and treatment of SGC.

View Figures

View References

1	Cook BJ and Bartley GB: Treatment options and future prospects for the management of eyelid malignancies: An evidence-based update. Ophthalmology. 108:2088–2098, 2099-2100. 2001. View Article : Google Scholar : PubMed/NCBI
2	Wang L, Shan Y, Dai X, You N, Shao J, Pan X, Gao T and Ye J: Clinicopathological analysis of 5146 eyelid tumours and tumour-like lesions in an eye centre in South China, 2000–2018: A retrospective cohort study. BMJ Open. 11:e0418542021. View Article : Google Scholar : PubMed/NCBI
3	Kaliki S, Ayyar A, Dave TV, Ali MJ, Mishra DK and Naik MN: Sebaceous gland carcinoma of the eyelid: Clinicopathological features and outcome in Asian Indians. Eye (Lond). 29:958–963. 2015. View Article : Google Scholar : PubMed/NCBI
4	Watanabe A, Sun MT, Pirbhai A, Ueda K, Katori N and Selva D: Sebaceous carcinoma in Japanese patients: Clinical presentation, staging and outcomes. Br J Ophthalmol. 97:1459–1463. 2013. View Article : Google Scholar : PubMed/NCBI
5	Cicinelli MV and Kaliki S: Ocular sebaceous gland carcinoma: An update of the literature. Int Ophthalmol. 39:1187–1197. 2019. View Article : Google Scholar : PubMed/NCBI
6	Esmaeli B, Nasser QJ, Cruz H, Fellman M, Warneke CL and Ivan D: American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival. Ophthalmology. 119:1078–1082. 2012. View Article : Google Scholar : PubMed/NCBI
7	Zhou C, Shi Y, Chai P, Wu F, Xia W, He X, Shi Y, Huang H, Jia R and Fan X: Contemporary update of overall prognosis and nomogram to predict individualized survival for Chinese patients with eyelid sebaceous carcinoma. EBioMedicine. 36:221–228. 2018. View Article : Google Scholar : PubMed/NCBI
8	Shields JA, Demirci H, Marr BP, Eagle RC Jr and Shields CL: Sebaceous carcinoma of the eyelids: Personal experience with 60 cases. Ophthalmology. 111:2151–2157. 2004. View Article : Google Scholar : PubMed/NCBI
9	Hirano T, Yunoki T, Furusawa Y, Tabuchi Y and Hayashi A: Bioinformatics analysis of the microRNA-mRNA network in sebaceous gland carcinoma of the eyelid. Mol Med Rep. 23:232021.PubMed/NCBI
10	Bhardwaj M, Sen S, Chosdol K, Sharma A, Pushker N, Kashyap S, Bakhshi S and Bajaj MS: miRNA-200c and miRNA-141 as potential prognostic biomarkers and regulators of epithelial-mesenchymal transition in eyelid sebaceous gland carcinoma. Br J Ophthalmol. 101:536–542. 2017. View Article : Google Scholar : PubMed/NCBI
11	Dang X, Lin H, Li Y, Guo X, Yuan Y, Zhang R, Li X, Chai D and Zuo Y: MicroRNA profiling in BEAS-2B cells exposed to alpha radiation reveals potential biomarkers for malignant cellular transformation. Toxicol Res (Camb). 9:834–844. 2020. View Article : Google Scholar : PubMed/NCBI
12	Kocyigit I, Taheri S, Sener EF, Eroglu E, Ozturk F, Unal A, Korkmaz K, Zararsiz G, Sipahioglu MH, Ozkul Y, et al: Serum micro-rna profiles in patients with autosomal dominant polycystic kidney disease according to hypertension and renal function. BMC Nephrol. 18:1792017. View Article : Google Scholar : PubMed/NCBI
13	Adams JC and Lawler J: The thrombospondins. Cold Spring Harb Perspect Biol. 3:a0097122011. View Article : Google Scholar : PubMed/NCBI
14	Huang C, Zhou X, Li Z, Liu H, He Y, Ye G and Huang K: Downregulation of thrombospondin-1 by DNA hypermethylation is associated with tumor progression in laryngeal squamous cell carcinoma. Mol Med Rep. 14:2489–2496. 2016. View Article : Google Scholar : PubMed/NCBI
15	Huang WT, Chong IW, Chen HL, Li CY, Hsieh CC, Kuo HF, Chang CY, Chen YH, Liu YP, Lu CY, et al: Pigment epithelium-derived factor inhibits lung cancer migration and invasion by upregulating exosomal thrombospondin 1. Cancer Lett. 442:287–298. 2019. View Article : Google Scholar : PubMed/NCBI
16	Lin T, Zhu L, Zhou B, Xie L, Lv J, Dong L and He Y: Establishment and characterization of a cell line from human adenoid cystic carcinoma of the lacrimal glands and a nude mouse transplantable model. Oncol Rep. 33:2797–2806. 2015. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. eLife. 4:42015. View Article : Google Scholar
19	Liu W and Wang X: Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 20:182019. View Article : Google Scholar : PubMed/NCBI
20	Pe'er J: Pathology of eyelid tumors. Indian J Ophthalmol. 64:177–190. 2016. View Article : Google Scholar : PubMed/NCBI
21	Satomura H, Ogata D, Arai E and Tsuchida T: Dermoscopic features of ocular and extraocular sebaceous carcinomas. J Dermatol. 44:1313–1316. 2017. View Article : Google Scholar : PubMed/NCBI
22	Muqit MM, Foot B, Walters SJ, Mudhar HS, Roberts F and Rennie IG: Observational prospective cohort study of patients with newly-diagnosed ocular sebaceous carcinoma. Br J Ophthalmol. 97:47–51. 2013. View Article : Google Scholar : PubMed/NCBI
23	Buitrago W and Joseph AK: Sebaceous carcinoma: The great masquerader: Emgerging concepts in diagnosis and treatment. Dermatol Ther. 21:459–466. 2008. View Article : Google Scholar : PubMed/NCBI
24	Goto H, Tsubota K, Nemoto R, Ueda S, Umazume K, Usui Y and Matsumura H: Clinical features and prognosis of sebaceous carcinoma arising in the eyelid or conjunctiva. Jpn J Ophthalmol. 64:549–554. 2020. View Article : Google Scholar : PubMed/NCBI
25	Owen JL, Kibbi N, Worley B, Kelm RC, Wang JV, Barker CA, Behshad R, Bichakjian CK, Bolotin D, Bordeaux JS, et al: Sebaceous carcinoma: Evidence-based clinical practice guidelines. Lancet Oncol. 20:e699–e714. 2019. View Article : Google Scholar : PubMed/NCBI
26	Tang S, Li S, Liu T, He Y, Hu H, Zhu Y, Tang S and Zhou H: MicroRNAs: Emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in lung cancer. Cancer Lett. 502:71–83. 2021. View Article : Google Scholar : PubMed/NCBI
27	Bladen JC, Wang J, Sangaralingam A, Moosajee M, Fitchett C, Chelala C, Beaconsfield M, O'Toole EA, Philpott MP and Ezra DG: MicroRNA and transcriptome analysis in periocular Sebaceous Gland Carcinoma. Sci Rep. 8:75312018. View Article : Google Scholar : PubMed/NCBI
28	Tetzlaff MT, Curry JL, Yin V, Pattanaprichakul P, Manonukul J, Uiprasertkul M, Manyam GC, Wani KM, Aldape K, Zhang L, et al: Distinct pathways in the pathogenesis of sebaceous carcinomas implicated by differentially expressed microRNAs. JAMA Ophthalmol. 133:1109–1116. 2015. View Article : Google Scholar : PubMed/NCBI
29	Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, Wimmer DA, Ning J, Czerniak BA, Zhang L, et al: Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol. 240:84–95. 2016. View Article : Google Scholar : PubMed/NCBI
30	Bao Y, Selfridge JE, Wang J, Zhao Y, Cui J, Guda K, Wang Z and Zhu Y: Mutations in TP53, ZNF750, and RB1 typify ocular sebaceous carcinoma. J Genet Genomics. 46:315–318. 2019. View Article : Google Scholar : PubMed/NCBI
31	Tetzlaff MT, Curry JL, Ning J, Sagiv O, Kandl TL, Peng B, Bell D, Routbort M, Hudgens CW, Ivan D, et al: distinct biological types of ocular adnexal sebaceous carcinoma: HPV-driven and virus-negative tumors arise through nonoverlapping molecular-genetic alterations. Clin Cancer Res. 25:1280–1290. 2019. View Article : Google Scholar : PubMed/NCBI
32	Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, Folkman J, Italiano JE Jr and Ryeom S: Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood. 115:4605–4613. 2010. View Article : Google Scholar : PubMed/NCBI
33	Yang W, Li W, Pan F, Yang XY, Zhao X, Qin L and Pan Y: TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar. Oncol Lett. 19:2107–2114. 2020.PubMed/NCBI
34	Sevilla-Montero J, Bienes-Martínez R, Labrousse-Arias D, Fuertes-Yebra E, Ordóñez Á and Calzada MJ: pVHL-mediated regulation of the anti-angiogenic protein thrombospondin-1 decreases migration of clear cell renal carcinoma cell lines. Sci Rep. 10:11752020. View Article : Google Scholar : PubMed/NCBI
35	Rouanne M, Adam J, Goubar A, Robin A, Ohana C, Louvet E, Cormier J, Mercier O, Dorfmüller P, Fattal S, et al: Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. BMC Cancer. 16:4832016. View Article : Google Scholar : PubMed/NCBI
36	Pal SK, Nguyen CT, Morita KI, Miki Y, Kayamori K, Yamaguchi A and Sakamoto K: THBS1 is induced by TGFB1 in the cancer stroma and promotes invasion of oral squamous cell carcinoma. J Oral Pathol Med. 45:730–739. 2016. View Article : Google Scholar : PubMed/NCBI
37	Cen J, Feng L, Ke H, Bao L, Li LZ, Tanaka Y, Weng J and Su L: Exosomal thrombospondin-1 disrupts the integrity of endothelial intercellular junctions to facilitate breast cancer cell metastasis. Cancers (Basel). 11:112019. View Article : Google Scholar